---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-007867"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T17:05:48.713913+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics settles Ladenburg lawsuit; issues warrant and agrees to pay $3.1M

## Summary
- Issued warrant for 300,000 shares at $0.5424 per share and paid $500K cash upfront.
- Must pay $1.5M by June 30, 2023, and $1.1M by Dec 31, 2023, in cash or stock at Company's option.
- Ladenburg Action will be dismissed with prejudice after obligations completed.
- Warrant issued under Section 4(a)(2) and Rule 506 of Regulation D as unregistered sale.

## SEC filing metadata
- accession: 0001437749-23-007867
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.03, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/0001437749-23-007867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/sabs20230324_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-007867
- JSON: https://secwatch.observer/filing/0001437749-23-007867.json
- Plain text: https://secwatch.observer/filing/0001437749-23-007867.txt

## Key facts
- Debt Financings
  SAB Biotherapeutics, Inc. incurred debt of pay $1.5 million to Ladenburg in cash or shares of common stock, at the Company’s option; and (ii) no later than Decembe with Ladenburg Thalmann & Co. Inc. maturing December 31, 2023.
  - Principal: pay $1.5 million to Ladenburg in cash or shares of common stock, at the Company’s option; and (ii) no later than Decembe
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Maturity: December 31, 2023
  - Event: incurrence
  source text: On March 21, 2023, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a settlement agreement with Ladenburg Thalmann & Co. Inc. (the “2023 Ladenburg Agreement”, and the action brought by Ladenburg, the “Ladenburg Action”), effective March 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000143774923007867/0001437749-23-007867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.